Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

Trial Profile

A Multicenter, Randomized, Open-label, Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2018

At a glance

  • Drugs Asunercept (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors CANbridge Life Sciences
  • Most Recent Events

    • 15 Nov 2018 Status changed from planning to not yet recruiting.
    • 17 Apr 2018 New trial record
    • 12 Apr 2018 According to a CANbridge Life Sciences media release, company anticipates dosing the first patient later this year
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top